Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Chief Human Resources Officer | April 02, 2026 | April 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date April 02, 2026 · Filed April 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,443 |
Ending reported balance
After 2026-04-06 transaction · row 14
14 source rows · reconciled sequenceRow 1 · 2026-04-02 · Sale · Disposed 265 · Balance 13,088 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $316.04 to $317.03. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2026-04-02 · Sale · Disposed 359 · Balance 12,729 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $317.07 to $318.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-04-02 · Sale · Disposed 209 · Balance 12,520 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.09 to $318.83. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-04-02 · Sale · Disposed 86 · Balance 12,434 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.19 to $320.10. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2026-04-02 · Sale · Disposed 147 · Balance 12,287 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.21 to $321.11. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2026-04-02 · Sale · Disposed 224 · Balance 12,063 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.26 to $322.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 7 · 2026-04-02 · Sale · Disposed 245 · Balance 11,818 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.31 to $323.13. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2026-04-02 · Sale · Disposed 81 · Balance 11,737 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.39 to $324.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 9 · 2026-04-02 · Sale · Disposed 8 · Balance 11,729 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. Row 10 · 2026-04-06 · Sale · Disposed 56 · Balance 11,673 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025. F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.10 to $320.32. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 11 · 2026-04-06 · Sale · Disposed 909 · Balance 10,764 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025. F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.22 to $330.18. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 12 · 2026-04-06 · Sale · Disposed 829 · Balance 9,935 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025. F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.21 to $330.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 13 · 2026-04-06 · Sale · Disposed 293 · Balance 9,642 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025. F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.77 to $332.14. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 14 · 2026-04-06 · Sale · Disposed 199 · Balance 9,443 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025. F15: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $333.39 to $334.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units.
F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $316.04 to $317.03. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $317.07 to $318.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.09 to $318.83. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.19 to $320.10. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.21 to $321.11. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.26 to $322.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.31 to $323.13. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.39 to $324.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025.
F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.10 to $320.32. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.22 to $330.18. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.21 to $330.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.77 to $332.14. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F15: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $333.39 to $334.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 06, 2026 Filed Apr 7, 2026 20:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 199 | $333.94 | $66,454.06 |
DisclosureSEC source: 0001178670-26-000014 · form4.xml · nonDerivative · entry 14 McLaughlin Melissa · CIK 0002127187 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,443 F10 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025. F15 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $333.39 to $334.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 20:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 293 | $331.89 | $97,243.77 |
DisclosureSEC source: 0001178670-26-000014 · form4.xml · nonDerivative · entry 13 McLaughlin Melissa · CIK 0002127187 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,642 F10 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.77 to $332.14. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 20:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 829 | $330.46 | $273,951.34 |
DisclosureSEC source: 0001178670-26-000014 · form4.xml · nonDerivative · entry 12 McLaughlin Melissa · CIK 0002127187 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,935 F10 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.21 to $330.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 20:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 909 | $329.76 | $299,751.84 |
DisclosureSEC source: 0001178670-26-000014 · form4.xml · nonDerivative · entry 11 McLaughlin Melissa · CIK 0002127187 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,764 F10 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.22 to $330.18. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 20:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 56 | $320.14 | $17,927.84 |
DisclosureSEC source: 0001178670-26-000014 · form4.xml · nonDerivative · entry 10 McLaughlin Melissa · CIK 0002127187 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,673 F10 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.10 to $320.32. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 02, 2026 Filed Apr 7, 2026 20:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 8 | $325.49 | $2,603.92 |
DisclosureSEC source: 0001178670-26-000014 · form4.xml · nonDerivative · entry 9 McLaughlin Melissa · CIK 0002127187 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,729 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. Read SEC document |
| April 02, 2026 Filed Apr 7, 2026 20:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 81 | $323.64 | $26,214.84 |
DisclosureSEC source: 0001178670-26-000014 · form4.xml · nonDerivative · entry 8 McLaughlin Melissa · CIK 0002127187 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,737 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.39 to $324.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 02, 2026 Filed Apr 7, 2026 20:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 245 | $322.86 | $79,100.70 |
DisclosureSEC source: 0001178670-26-000014 · form4.xml · nonDerivative · entry 7 McLaughlin Melissa · CIK 0002127187 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,818 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.31 to $323.13. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 02, 2026 Filed Apr 7, 2026 20:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 224 | $321.64 | $72,047.36 |
DisclosureSEC source: 0001178670-26-000014 · form4.xml · nonDerivative · entry 6 McLaughlin Melissa · CIK 0002127187 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,063 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.26 to $322.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 02, 2026 Filed Apr 7, 2026 20:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 147 | $320.62 | $47,131.14 |
DisclosureSEC source: 0001178670-26-000014 · form4.xml · nonDerivative · entry 5 McLaughlin Melissa · CIK 0002127187 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,287 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.21 to $321.11. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 02, 2026 Filed Apr 7, 2026 20:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 86 | $319.69 | $27,493.34 |
DisclosureSEC source: 0001178670-26-000014 · form4.xml · nonDerivative · entry 4 McLaughlin Melissa · CIK 0002127187 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,434 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.19 to $320.10. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 02, 2026 Filed Apr 7, 2026 20:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 209 | $318.47 | $66,560.23 |
DisclosureSEC source: 0001178670-26-000014 · form4.xml · nonDerivative · entry 3 McLaughlin Melissa · CIK 0002127187 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,520 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.09 to $318.83. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 02, 2026 Filed Apr 7, 2026 20:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 359 | $317.44 | $113,960.96 |
DisclosureSEC source: 0001178670-26-000014 · form4.xml · nonDerivative · entry 2 McLaughlin Melissa · CIK 0002127187 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,729 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $317.07 to $318.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 02, 2026 Filed Apr 7, 2026 20:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 265 | $316.61 | $83,901.65 |
DisclosureSEC source: 0001178670-26-000014 · form4.xml · nonDerivative · entry 1 McLaughlin Melissa · CIK 0002127187 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,088 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $316.04 to $317.03. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.